Over 90 per cent of the subjects in the phase 1 trials developed an immune response to HIV. ”Never has such a good result been seen with a vaccine of this type,” says Professor Eric Sandström, Chief Physician at Karolinska University Hospital.
A vaccine developed by SMI scientists has now undergone the first clinical study on healthy individuals in Sweden in order to examine its safety and different methods of administration. The vaccine is what is known as a genetic vaccine, which uses parts of the virus DNA to stimulate the rapid endogenous production of the proteins for which the injected DNA codes.
The trial subjects were vaccinated on three occasions with this vaccine using a needle-free method of injection. In order to enhance the effect, the researchers also gave the subjects a fourth dose of a vaccine in which parts of the HIV virus DNA had been integrated into another virus (vaccinia = the cowpox virus). This vaccine-based HIV vaccine is produced by the USA’s National Institutes of Health and was donated for use in this Swedish study.
“Our vaccine is designed in such a way that it’s able to protect against many of the circulating HIV types in Africa and the West,” says Professor Britta Wahren at the SMI/KI.
Over 90 per cent of the trial subjects developed an immune response to HIV, and the vaccines have been tolerated well.
Data from the study will be presented at the four-day HIV vaccine conference in Amsterdam starting 29 August under the heading “Multigene, multiclade HIV-1 plasmid DNA prime and MVA boost is safe and highly immunogenic in healthy human volunteers”.
Scientists now hope to follow up the Swedish study with a larger phase 1 – phase 2 study in Tanzania, planned to commence this autumn, in order to corroborate the Swedish results on African subjects and to help train Tanzanians to carry out parts of the study, including sophisticated laboratory examinations, on site.
The project is being led by KI professors Gunnel Biberfeld and Britta Wahren at the SMI and Eric Sandström at Karolinska University Hospital.
SMI has been running major projects in the HIV field since 1986 with the support of Sida/SAREC, the EU’s 5th Framework Programme, the Swedish Research Council, Karolinska Institutet, and Karolinska University Hospital. Over the past few years, the projects have tended more and more towards developing a vaccine for the prevention of HIV.
Data from the study will be released at the conference presentation on 30 August.
Katarina Sternudd | alfa
Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine